It's the deal falls over and the value of NTC is recognised by the market as being more than $1.10, then UBS could make a substantial gain. I think UBS might make their own luck here.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
